Skip to main content
Premium Trial:

Request an Annual Quote

Johnson Pharmaceutical Research Institute Joins NaviCyte Consortium

Premium

SAN DIEGO, Calif.--NaviCyte, a wholly owned subsidiary of Trega Biosciences, entered an agreement with the R.W. Johnson Pharmaceutical Research Institute to collaborate on the development of NaviCyte's pharmacokinetic informatics tools for drug target selection. The research institute will provide data and make initial and milestone payments during development of NaviCyte's In Vitro Determination for Evaluation of Absorption (Idea) simulation software system and database. The tools are designed to enable prediction of pharmacokinetic outcomes in humans.

SmithKline Beecham, Genentech, Parke-Davis, and Schering Plough are also members of NaviCyte's consortium.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.